izpis_h1_title_alt

New dual inhibitors of bacterial topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against vancomycin-intermediate Staphylococcus aureus
ID Durcik, Martina (Author), ID Cotman, Andrej Emanuel (Author), ID Toplak, Žan (Author), ID Možina, Štefan (Author), ID Skok, Žiga (Author), ID Piras, Maria Vittoria (Author), ID Zidar, Nace (Author), ID Ilaš, Janez (Author), ID Zega, Anamarija (Author), ID Trontelj, Jurij (Author), ID Kikelj, Danijel (Author), ID Tomašič, Tihomir (Author), ID Peterlin-Mašič, Lucija (Author), et al.

.pdfPDF - Presentation file, Download (4,53 MB)
MD5: 5DD9CC02507A37180CB47A24D863D63C
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01905 This link opens in a new window

Abstract
A new series of dual low nanomolar benzothiazole inhibitors of bacterial DNA gyrase and topoisomerase IV were developed. The resulting compounds show excellent broad-spectrum antibacterial activities against Gram-positive Enterococcus faecalis, Enterococcus faecium and multidrug resistant (MDR) Staphylococcus aureus strains [best compound minimal inhibitory concentrations (MICs): range, <0.03125–0.25 μg/mL] and against the Gram-negatives Acinetobacter baumannii and Klebsiella pneumoniae (best compound MICs: range, 1–4 μg/mL). Lead compound 7a was identified with favorable solubility and plasma protein binding, good metabolic stability, selectivity for bacterial topoisomerases, and no toxicity issues. The crystal structure of 7a in complex with Pseudomonas aeruginosa GyrB24 revealed its binding mode at the ATP-binding site. Expanded profiling of 7a and 7h showed potent antibacterial activity against over 100 MDR and non-MDR strains of A. baumannii and several other Gram-positive and Gram-negative strains. Ultimately, in vivo efficacy of 7a in a mouse model of vancomycin-intermediate S. aureus thigh infection was also demonstrated.

Language:English
Keywords:antibacterial activity, bacteria, inhibitors, genetics, inhibition, peptides and proteins
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:Str. 3968-3994
Numbering:Vol. 66, iss. 6
PID:20.500.12556/RUL-145096 This link opens in a new window
UDC:615.015.8
ISSN on article:1520-4804
DOI:10.1021/acs.jmedchem.2c01905 This link opens in a new window
COBISS.SI-ID:144333571 This link opens in a new window
Publication date in RUL:05.04.2023
Views:413
Downloads:72
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of medicinal chemistry
Shortened title:J. med. chem.
Publisher:American Chemical Society
ISSN:1520-4804
COBISS.SI-ID:512806681 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:antibakterijsko delovanje, zaviralci, nanomolarni inhibitorji benzotiazola, topoizomeraza IV, farmacevtska kemija, bakterije, bakterijska rezistenca

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J1-3030
Name:MTAvsAMR: novi večtarčni antibiotiki proti večkratno odpornim bakterijam

Funder:ARRS - Slovenian Research Agency
Project number:J1-3031
Name:Razvoj novih zaviralcev bakterijskih topoizomeraz za boj proti odpornim infekcijam

Funder:ARRS - Slovenian Research Agency
Project number:BI-HU/19-20-008

Funder:EC - European Commission
Funding programme:FP7
Project number:115583
Name:European Gram Negative Antibacterial Engine
Acronym:ENABLE

Funder:UKRI - UK Research and Innovation
Funding programme:BBSRC
Project number:BB/J014524/1

Funder:Other - Other funder or multiple funders
Funding programme:Redx Pharma Plc, iCASE studentship

Funder:WT - Wellcome Trust
Funding programme:Investigator Award
Project number:110072/Z/15/Z

Funder:UKRI - UK Research and Innovation
Funding programme:BBSRC, Institute Strategic Programme
Project number:BB/P012523/1

Funder:Other - Other funder or multiple funders
Funding programme:National Research Development and Innovation Office, Élvonal Programme
Project number:KKP 126506

Funder:Other - Other funder or multiple funders
Funding programme:ELKH, Lendület Programme
Project number:LP-2017–10/2020

Funder:Other - Other funder or multiple funders
Funding programme:National Laboratory of Biotechnology
Project number:NKFIH-871-3/2020

Funder:Other - Other funder or multiple funders
Funding programme:National Laboratory of Biotechnology
Project number:2022-2.1.1-NL-2022-00008

Funder:EC - European Commission
Funding programme:H2020
Project number:648364
Name:Bacterial evolution of hypersensitivity and resistance against antimicrobial peptides
Acronym:Resistance evolution

Funder:Other - Other funder or multiple funders
Funding programme:Ministry for Culture and Innovation, National Research, Development and Innovation Fund, New National Excellence Program, ÚNKP-22-4

Funder:Other - Other funder or multiple funders
Funding programme:Hungary, Ministry of Culture and Innovation, National Biomedical Foundation, National Academy of Scientist Education Program

Funder:Other - Other funder or multiple funders
Funding programme:Ministry for Culture and Innovation, National Research, Development and Innovation Fund, New National Excellence Program, ÚNKP-22-2

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back